Clinical Trial Update: A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 [Phase 1]

View source ↗

Summary

Phase 1/1b trial evaluating RNDO-564 as a single agent or in combination with pembrolizumab in bladder cancer and nectin-4–associated solid tumors is enrolling …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• RNDO-564

Snippet

Sponsor: Rondo Therapeutics | Conditions: Non Small Cell Lung Cancer, Cervical Cancer | Phase 1 | Status: ENROLLING_BY_INVITATION